A detailed history of Vanguard Group Inc transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Vanguard Group Inc holds 9,402,246 shares of DVAX stock, worth $105 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,402,246
Previous 9,275,788 1.36%
Holding current value
$105 Million
Previous $130 Million 10.02%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$11.7 - $14.98 $1.48 Million - $1.89 Million
126,458 Added 1.36%
9,402,246 $117 Million
Q4 2023

Feb 14, 2024

BUY
$13.09 - $14.98 $1.69 Million - $1.93 Million
128,897 Added 1.41%
9,275,788 $130 Million
Q3 2023

Nov 14, 2023

BUY
$12.64 - $14.99 $3.42 Million - $4.06 Million
270,730 Added 3.05%
9,146,891 $135 Million
Q2 2023

Aug 14, 2023

BUY
$9.85 - $13.17 $4.19 Million - $5.6 Million
425,263 Added 5.03%
8,876,161 $115 Million
Q1 2023

May 15, 2023

BUY
$9.44 - $11.88 $1 Million - $1.26 Million
106,036 Added 1.27%
8,450,898 $82.9 Million
Q4 2022

Feb 10, 2023

BUY
$10.27 - $13.29 $1.84 Million - $2.38 Million
179,221 Added 2.19%
8,344,862 $88.8 Million
Q3 2022

Nov 14, 2022

BUY
$9.93 - $17.44 $1.41 Million - $2.47 Million
141,674 Added 1.77%
8,165,641 $85.2 Million
Q2 2022

Aug 12, 2022

BUY
$7.45 - $12.83 $16.2 Million - $28 Million
2,180,769 Added 37.32%
8,023,967 $101 Million
Q1 2022

May 13, 2022

SELL
$9.75 - $14.44 $595,832 - $882,442
-61,111 Reduced 1.04%
5,843,198 $63.3 Million
Q4 2021

Feb 14, 2022

BUY
$13.17 - $20.94 $3.74 Million - $5.94 Million
283,799 Added 5.05%
5,904,309 $83.1 Million
Q3 2021

Nov 12, 2021

SELL
$9.16 - $19.83 $1.51 Million - $3.27 Million
-164,866 Reduced 2.85%
5,620,510 $108 Million
Q2 2021

Aug 13, 2021

BUY
$7.25 - $10.99 $41.9 Million - $63.6 Million
5,785,376 New
5,785,376 $57 Million

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.42B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.